PT2043600T - Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas - Google Patents
Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticasInfo
- Publication number
- PT2043600T PT2043600T PT77300580T PT07730058T PT2043600T PT 2043600 T PT2043600 T PT 2043600T PT 77300580 T PT77300580 T PT 77300580T PT 07730058 T PT07730058 T PT 07730058T PT 2043600 T PT2043600 T PT 2043600T
- Authority
- PT
- Portugal
- Prior art keywords
- applications
- well
- active ingredient
- sustained release
- pharmaceutical formulations
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0605152A FR2902007B1 (fr) | 2006-06-09 | 2006-06-09 | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2043600T true PT2043600T (pt) | 2017-10-13 |
Family
ID=37603185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT77300580T PT2043600T (pt) | 2006-06-09 | 2007-06-11 | Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2043600B1 (pt) |
JP (1) | JP5351015B2 (pt) |
KR (2) | KR20140109512A (pt) |
CN (1) | CN101466353B (pt) |
AU (1) | AU2007255367B2 (pt) |
BR (1) | BRPI0712142A8 (pt) |
CA (1) | CA2653537C (pt) |
ES (1) | ES2642095T3 (pt) |
FR (1) | FR2902007B1 (pt) |
IL (1) | IL195269A (pt) |
MX (1) | MX2008015665A (pt) |
PT (1) | PT2043600T (pt) |
WO (1) | WO2007141344A2 (pt) |
ZA (1) | ZA200809864B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2915684B1 (fr) * | 2007-05-03 | 2011-01-14 | Flamel Tech Sa | Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules |
FR2954325B1 (fr) | 2009-12-23 | 2012-02-03 | Flamel Tech Sa | Polymere amphiphile fonctionnalise par la methionine |
JP4829351B2 (ja) * | 2010-02-05 | 2011-12-07 | ナノキャリア株式会社 | 易崩壊型ポリマーミセル組成物 |
KR101198137B1 (ko) | 2010-09-03 | 2012-11-12 | 에스케이하이닉스 주식회사 | 라이트 드라이버 및 이를 이용한 반도체 메모리 장치와 프로그램 방법 |
FR2968993B1 (fr) * | 2010-12-17 | 2012-12-28 | Flamel Tech Sa | Nanoparticules comportant au moins un actif et au moins deux polyelectrolytes |
FR2968994B1 (fr) * | 2010-12-17 | 2012-12-28 | Flamel Tech Sa | Procede de preparation de nanoparticules |
KR101239492B1 (ko) * | 2011-03-25 | 2013-03-05 | 서울대학교산학협력단 | 폴리소르비톨계 삼투압적 활성 전달체 및 이를 이용한 유전자 치료 |
DK2741765T3 (en) | 2011-08-10 | 2016-06-13 | Adocia | Injectable solution of at least one type of basal insulin |
CN102432695B (zh) * | 2011-10-28 | 2014-02-26 | 黑龙江大学 | N-2-羟丙基三甲基氯化铵壳聚糖负载新城疫减毒活疫苗纳米粒的制备方法 |
FR2985428B1 (fr) * | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
BR112014016889A8 (pt) | 2012-01-09 | 2017-07-04 | Adocia | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 |
FR2985429B1 (fr) * | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
EP2836533A1 (en) * | 2012-04-13 | 2015-02-18 | Wake Forest University | Low band gap conjugated polymeric compositions and applications thereof |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
EP3064213A4 (en) * | 2013-10-28 | 2017-04-26 | Terumo Kabushiki Kaisha | Protein aqueous suspension |
MX2017005692A (es) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
KR20190026748A (ko) * | 2016-06-07 | 2019-03-13 | 아도시아 | 인간 글루카곤 및 말단-그래프트된 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물 |
KR102218427B1 (ko) * | 2017-09-20 | 2021-02-22 | 차의과학대학교 산학협력단 | 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제 |
WO2022126100A1 (en) * | 2020-12-09 | 2022-06-16 | Lynthera Corporation | Boundary surface charged contact lens for delivery |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5500161A (en) * | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
FR2732218B1 (fr) * | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
AU3916997A (en) * | 1996-08-19 | 1998-03-06 | Vivorx Pharmaceuticals, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
FR2786098B1 (fr) * | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
FR2801226B1 (fr) * | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
FR2860516B1 (fr) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques |
FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
-
2006
- 2006-06-09 FR FR0605152A patent/FR2902007B1/fr active Active
-
2007
- 2007-06-11 ES ES07730058.0T patent/ES2642095T3/es active Active
- 2007-06-11 WO PCT/EP2007/055720 patent/WO2007141344A2/fr active Application Filing
- 2007-06-11 BR BRPI0712142A patent/BRPI0712142A8/pt not_active Application Discontinuation
- 2007-06-11 KR KR1020147023768A patent/KR20140109512A/ko not_active Application Discontinuation
- 2007-06-11 AU AU2007255367A patent/AU2007255367B2/en active Active
- 2007-06-11 ZA ZA200809864A patent/ZA200809864B/xx unknown
- 2007-06-11 KR KR1020097000533A patent/KR101463952B1/ko not_active IP Right Cessation
- 2007-06-11 CA CA2653537A patent/CA2653537C/fr active Active
- 2007-06-11 CN CN200780021416.XA patent/CN101466353B/zh active Active
- 2007-06-11 PT PT77300580T patent/PT2043600T/pt unknown
- 2007-06-11 JP JP2009513711A patent/JP5351015B2/ja active Active
- 2007-06-11 MX MX2008015665A patent/MX2008015665A/es active IP Right Grant
- 2007-06-11 EP EP07730058.0A patent/EP2043600B1/fr active Active
-
2008
- 2008-11-13 IL IL195269A patent/IL195269A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP5351015B2 (ja) | 2013-11-27 |
BRPI0712142A8 (pt) | 2016-03-29 |
BRPI0712142A2 (pt) | 2012-01-10 |
CA2653537C (fr) | 2014-07-29 |
WO2007141344B1 (fr) | 2008-05-22 |
IL195269A (en) | 2014-06-30 |
CN101466353A (zh) | 2009-06-24 |
EP2043600B1 (fr) | 2017-07-26 |
FR2902007B1 (fr) | 2012-01-13 |
KR20140109512A (ko) | 2014-09-15 |
ZA200809864B (en) | 2010-03-31 |
IL195269A0 (en) | 2009-08-03 |
AU2007255367B2 (en) | 2012-08-02 |
EP2043600A2 (fr) | 2009-04-08 |
MX2008015665A (es) | 2009-01-09 |
KR20090040289A (ko) | 2009-04-23 |
KR101463952B1 (ko) | 2014-11-26 |
FR2902007A1 (fr) | 2007-12-14 |
CA2653537A1 (fr) | 2007-12-13 |
WO2007141344A2 (fr) | 2007-12-13 |
WO2007141344A3 (fr) | 2008-04-10 |
CN101466353B (zh) | 2014-09-03 |
JP2009539810A (ja) | 2009-11-19 |
AU2007255367A1 (en) | 2007-12-13 |
ES2642095T3 (es) | 2017-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
TWI366460B (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
EP2130552A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE | |
ZA200705530B (en) | Sustained release pharmaceutical formulations | |
EP2078731A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
ZA200900345B (en) | Preparation of pharmaceutical formulations | |
IL233677A (en) | Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition | |
HK1128471A1 (en) | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents | |
IL212435A (en) | Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs | |
IL199397A (en) | Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products | |
IL185390A (en) | A solid dosage form | |
WO2009117130A3 (en) | Extended release forumulation containing a wax | |
IL199835A (en) | Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation | |
EP2093237A4 (en) | ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
EP1895991A4 (en) | MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS | |
IL180031A0 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
EP2112925A4 (en) | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS | |
EP2045253A4 (en) | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient | |
EP2142549A4 (en) | ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE | |
WO2010021607A3 (en) | Pharmaceutical formulation | |
IL201465A0 (en) | Self-precipitating pharmaceutical formulations for the modified release of active principle | |
ZA200804427B (en) | Nanoparticulate active ingredient formulations | |
WO2007090661A3 (en) | Active substance combination comprising azolylcarbinol compounds | |
IL191758A0 (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
WO2011019326A3 (en) | Solubility and stability enchancing pharmaceutical formulation |